Subject(s)
Budgets , Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , Research Support as Topic , Research/economics , COVID-19 , Coronavirus Infections/economics , Education, Graduate/economics , Humans , Pandemics/economics , Pneumonia, Viral/economics , Research Personnel/economics , Universities/economicsSubject(s)
Budgets , Research , Republic of Korea , Research/economics , Research/standards , Research/trends , Research Support as TopicSubject(s)
Investments/statistics & numerical data , Research Support as Topic/economics , Research/economics , Unemployment/statistics & numerical data , Universities/economics , Budgets , COVID-19 , Coronavirus Infections/epidemiology , Education, Distance/economics , Faculty/statistics & numerical data , Humans , Investments/economics , Investments/trends , Pandemics , Pneumonia, Viral/epidemiology , Students/statistics & numerical data , Unemployment/trendsABSTRACT
Over the past decade, Pfizer has focused efforts to improve its research and development (R&D) productivity. By the end of 2020, Pfizer had achieved an industry-leading clinical success rate of 21%, a tenfold increase from 2% in 2010 and well above the industry benchmark of â¼11%. The company had also maintained the quality of innovation, because 75% of its approvals between 2016 and 2020 had at least one expedited regulatory designation (e.g., Breakthrough Therapy). Pfizer's Signs of Clinical Activity (SOCA) paradigm enabled better decision-making and, along with other drivers (biology and modality), contributed to this productivity improvement. These laid a strong foundation for the rapid and effective development of the Coronavirus 2019 (COVID-19) vaccine with BioNTech, as well as the antiviral candidate Paxlovid™, under the company's 'lightspeed' paradigm.
Subject(s)
Drug Industry/economics , Research/economics , Antiviral Agents/economics , BNT162 Vaccine/economics , COVID-19/economics , COVID-19 Vaccines/economics , HumansSubject(s)
HIV Infections/prevention & control , Anti-HIV Agents/therapeutic use , Financial Management , Global Health , HIV Infections/economics , HIV Infections/epidemiology , HIV Infections/virology , HIV-1/drug effects , HIV-1/physiology , Humans , Research/economics , South Africa/epidemiologySubject(s)
Financing, Government , Firearms/statistics & numerical data , Gun Violence/statistics & numerical data , Research Personnel/economics , Research Support as Topic , Research/economics , Centers for Disease Control and Prevention, U.S./economics , Child , Female , Gun Violence/prevention & control , Humans , Male , Pregnancy , United States/epidemiologyABSTRACT
Despite being among the world's leaders in scientific output, Brazil ranks 66th among countries in the production of reagents and supplies needed for state-of-the-art scientific analyses. The production of needed reagents and equipment for experimental analyses and patient diagnostics is sorely lacking within Brazil and explicit in this pandemic period caused by SARS-CoV-2. A significant fraction of resources from Brazilian funding agencies is now being transferred to companies in other countries for the purchase of essential scientific-related products. Is this sustainable? Therefore it is necessary to draw the attention of all the world and Brazilian society about this situation.
Subject(s)
COVID-19/economics , COVID-19/epidemiology , Research/economics , SARS-CoV-2 , Biomedical Technology , Biotechnology , Brazil/epidemiology , HumansSubject(s)
COVID-19 , Climate Change/statistics & numerical data , Disaster Planning/trends , Environmental Science/trends , Forecasting/methods , Research/organization & administration , Research/trends , Acclimatization , COVID-19/epidemiology , Climate Change/economics , Disaster Planning/economics , Disaster Planning/methods , Disasters/economics , Disasters/prevention & control , Disasters/statistics & numerical data , Environmental Policy , Environmental Science/economics , Environmental Science/methods , Global Warming/economics , Global Warming/prevention & control , Global Warming/statistics & numerical data , Humans , Public-Private Sector Partnerships , Research/economics , Risk ManagementSubject(s)
Financial Management/economics , Global Health/economics , Research/economics , Academies and Institutes/economics , Academies and Institutes/organization & administration , Financial Management/organization & administration , Humans , Research/organization & administration , United KingdomSubject(s)
COVID-19 , Research/economics , Developing Countries , Epidemics/prevention & control , HumansSubject(s)
Carbon Footprint , Congresses as Topic , Interprofessional Relations , Research , Science , Telecommunications , COVID-19 , Congresses as Topic/economics , Congresses as Topic/organization & administration , Congresses as Topic/trends , Humans , Research/economics , Research/organization & administration , Research/trends , Science/economics , Science/organization & administration , Science/trends , Telecommunications/economics , Telecommunications/organization & administration , Telecommunications/trendsSubject(s)
European Union/economics , Financing, Organized/economics , Financing, Organized/trends , Research Support as Topic/economics , Research Support as Topic/trends , Research/economics , Research/trends , COVID-19 , Data Management/economics , Entrepreneurship/economics , Europe , European Union/organization & administration , Female , Goals , Humans , Information Dissemination , International Cooperation , Male , Open Access Publishing/economics , Research/organization & administration , Research Personnel/economics , Sexism/prevention & control , Technology TransferSubject(s)
Burnout, Professional , COVID-19 , Faculty/psychology , Research Personnel/psychology , Research , Anxiety , COVID-19/epidemiology , Career Choice , Child , Child Rearing , Female , Humans , Leadership , Male , Pandemics , Research/economics , Research/organization & administration , Research Personnel/economics , Sex Factors , Stress, Psychological , Surveys and Questionnaires , Teaching , Teleworking , Uncertainty , Universities/economics , Work-Life Balance/statistics & numerical data , Workload/psychologyABSTRACT
The research and development (R&D) ecosystem has evolved over the past decade to include pandemic infectious diseases, building on experience from multiple recent outbreaks. Outcomes of this evolution have been particularly evident during the COVID-19 pandemic with accelerated development of vaccines and monoclonal antibodies, as well as novel clinical trial designs. These products were developed, trialled, manufactured, and authorised for use in several countries within a year of the pandemic's onset. Many gaps remain, however, that must be bridged to establish a truly efficient and effective end-to-end R&D preparedness and response ecosystem. Foremost among them is a global financing system. In addition, important changes are required for multiple aspects of enabling sciences and product development. For each of these elements we identify priorities for improved and faster functionality. There will be no better time than now to seriously address these needs, however difficult, as the ravages of COVID-19 continue to accelerate with devastating health, social, and economic consequences for the entire community of nations.
Subject(s)
Global Health , International Cooperation , Pandemics/prevention & control , Research/economics , Research/organization & administration , Humans , Models, OrganizationalSubject(s)
Coronavirus Infections/epidemiology , Financing, Organized/organization & administration , Pneumonia, Viral/epidemiology , Research Support as Topic/organization & administration , Research/economics , COVID-19 , COVID-19 Vaccines , Coronavirus Infections/drug therapy , Coronavirus Infections/economics , Coronavirus Infections/prevention & control , Decision Making , Drug Repositioning/economics , Humans , Pandemics/prevention & control , Pneumonia, Viral/drug therapy , Pneumonia, Viral/prevention & control , Time Factors , United Kingdom/epidemiology , Viral Vaccines/economics , COVID-19 Drug TreatmentSubject(s)
COVID-19 , Research Personnel/economics , Research Support as Topic/economics , Research/standards , Research/trends , COVID-19/economics , COVID-19/epidemiology , Humans , Motivation , Peer Review, Research , Preprints as Topic , Research/economics , Research Personnel/psychology , Research Personnel/standards , Research Support as Topic/trendsABSTRACT
As COVID-19 swept across the world, it created a global pandemic and an unpredictable and challenging job market. This article discusses the future of the 2020-2021 job market in both academia and industry in the midst and aftermath of this pandemic.